Gene-Editing Stocks Climb After Claims by Chinese Researcher

The transcript discusses the controversial announcement of human germline gene editing in China, raising ethical and regulatory concerns. It explores the impact on U.S. stocks and gene editing companies, highlighting the difference in regulatory approaches between the U.S. and China. The discussion also touches on the broader theme of a technological arms race with China, emphasizing the need for global agreements on new technologies.

What is the significance of the term 'designer babies' in the context of the text?

What are the ethical considerations mentioned in relation to gene editing technologies?